Trial Profile
A real world, multicenter,observational study to evaluate outcomes in patients with Rheumatoid arthritis treated with Intravenous Golimumab or Infliximab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 27 May 2017 New trial record
- 24 May 2017 Results presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research